A Meta-Analysis of Six Placebo-Controlled Trials of Thiazolidinedione Therapy for HIV Lipoatrophy

REFERENCES

• Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. New Engl J Med. 2005;352:48–62.
   PubMed Web of Science ®Google Scholar
• Mynarcik D, Wei LX, Komaroff E, Ferris R, McNurlan M, Gelato M. Chronic loss of subcutaneous adipose tissue in HIV-associated lipodystrophy may not be associated with accelerated apoptosis. J Acquir Immune Defic Syndr. 2005;38:367–371.
   PubMed Web of Science ®Google Scholar
• Roche R, Poizot-Martin I, Martin-El Yazidi C, Compe E, Gastaut J-A, Torresani J, Planells R. Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS. 2002;16:13–20.
   PubMed Web of Science ®Google Scholar
• Serghides L, Nathoo S, Walmsley S, Kain KC. CD36 deficiency induced by antiretroviral therapy. AIDS. 2002;16:353–358.
   PubMed Web of Science ®Google Scholar
• Miyaoka K, Kuwasako T, Hirano K, et al. CD36 deficiency associated with insulin resistance. Lancet. 2001;357: 686–687.
   PubMed Web of Science ®Google Scholar
• Aitman TJ. CD36, insulin resistance, and coronary heart disease. Lancet. 2001357: 651–652.
   Google Scholar
• Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-anologue reverse-transcriptase inhibitors is a key factor in the patho-genesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354:1112–1115.
   PubMed Web of Science ®Google Scholar
• Birkus G, Hitchcock MJ, Cihlar T. Assessment of mito-chondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46: 716–723.
   PubMed Web of Science ®Google Scholar
• Mallon PW, Unemori P, Sedwell R, et al; SAMA Investiga-tors. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabo-lism genes in the absence of depletion of mitochondrial DNA. J Infect Dis. 2005;191:1686–1696.
   PubMed Web of Science ®Google Scholar
• Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1 infected men starting therapy. AIDS. 2003;17:971–979.
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Riddler SA, DiRienzo AG, et al; AIDS Clinical Trials Group (ACTG) A5142 Study Team. Metabolic out-comes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009;23(9):1109–1118.
   PubMed Web of Science ®Google Scholar
• Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid disorders, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005;19:1807–1818.
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatro-phy and better lipid profile with abacavir as compared to stavudine: 96 week results of a randomized study. J Acquir Immune Defic Syndr 2007;44:139–147.
   PubMed Web of Science ®Google Scholar
• Arighu E, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med. 2000;133:263–274.
   PubMed Web of Science ®Google Scholar
• Mon Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajia N, et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care. 1999;22:908–912.
   PubMed Web of Science ®Google Scholar
• Kawai T, Takei I, Oguma Y, et al. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism. 1999;48:1102–1107.
   PubMed Web of Science ®Google Scholar
• Chiquette E, Ramirez G, DeFronzo R. A meta-analysis com-paring the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004;164:2097–2104.
   PubMed Web of Science ®Google Scholar
• Carr A, Workman C, Carey D, et al. No effect of rosigli-tazone for treatment of HIV-1 lipoatrophy: randomized, double-blind, placebo-controlled trial. Lancet. 2004;363: 429–438.
   PubMed Web of Science ®Google Scholar
• Sutinen J, Hakkinen AM, Westerbacka J, et al. Rosiglita-zone in the treatment of HAART-associated lipodystrophy: a randomized double-blind placebo-controlled study. Int Med Press. 2003;8:199–207.
   Google Scholar
• Cavalcanti R, Raboud JM, Shen S, Kain K, Cheung A, Walmsley S. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis. 2007;195(12)1 754–1761.
   Web of Science ®Google Scholar
• Hadigan C, Yawetz S, Thomas A, Havers F, Sax F, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med. 2006;140:786–795.
   Web of Science ®Google Scholar
• Mulligan K, Yang Y, Wininger D, et al. Effects of met-formin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS. 2007;21:47–57.
   PubMed Web of Science ®Google Scholar
• Slama L, Lanoy E, Valanin MA, et al. Effect of pioglitazone on HIV-1 related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antiviral Ther. 2008;13:67–76.
   PubMed Web of Science ®Google Scholar
• Zeger SL, Liang KY. Longitudinal data analysis of discrete and continuous outcomes. Biometrics. 1986;42:121–130.
   PubMed Web of Science ®Google Scholar
• El Bejjani D, Tungsiripat M, Rizk N, et al. Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. In : Program and abstracts from the 16th Conference on Retroviruses and Opportunistic Infec-tions; 2009. Abstract 42LB.
   Google Scholar
• Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syn-drome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659–1667.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008: 1–128. Available http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf Accessed May 1, 2008. [Table 18, page 83]
   Google Scholar
• Moyle G, Savin CA, Cartledge J, et al; RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. A random-ized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043–2050.
   PubMed Web of Science ®Google Scholar
• Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002288: 207–215.
   Google Scholar
• Martin A, Smith DE, Carr A, et al. Reversibility of lipoatro-phy in HIV-infected patients 2 years after switching from a thymidine analogue to Abacavir: the MITOX Extension Study. AIDS. 2004;18:1029–1036.
   PubMed Web of Science ®Google Scholar
• John M, McKinnon EJ, James IR, et al. Randomized, con-trolled, 48-week study of switching and/or protease inhibi-tors to combivir/Abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr. 2003;33:29–33.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38:263–270.
   PubMed Web of Science ®Google Scholar
• Gelato MC, Mynarcik DC, Quick JL, et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 2002;31:163–170.
   PubMed Web of Science ®Google Scholar
• Mallon PWG, Sedwell R, Rogers G, et al; for the Rosey Investigators. Adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction. J Infect Dis. 2008;198:1794–1803.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.
   PubMed Web of Science ®Google Scholar
• Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiret-roviral-näive patients: virologic, immunologic and morpho-logic changes - a 96 week analysis. J Acquir Immune Defic Syndr 2006;43:535–540.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Long-term risk of cardio-vascular events with rosiglitazone: a meta analysis. JAMA. 2007;298:1189–1195.
   PubMed Web of Science ®Google Scholar
• Nagajothi N, Adigopula S, Balamuthusamy S, et al. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials. Am J Ther. 2008;15(6): 506–511.
   PubMed Web of Science ®Google Scholar